LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

Home・Aandelen Lijst・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Gesloten

5.26 0.57

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.15

Max

5.34

Belangrijke statistieken
By Trading Economics
Inkomsten	2.1M -7.7M
EPS	-0.13
Winstmarge	-6,465.066
Werknemers	8
EBITDA	2.1M -7.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+74.8% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	613K 315M
Vorige openingsprijs	4.69
Vorige sluitingsprijs	5.26

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.9 / 2.65 Steun & Weerstand

Aldeyra Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2025, 22:40 UTC

Belangrijke Marktbewegers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

Peer Vergelijking

Prijswijziging

Aldeyra Therapeutics Inc Prognose

Koersdoel

By TipRanks

74.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.67 USD 74.8%

Hoogste 10 USD

Laagste 7 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aldeyra Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Aldeyra Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.9 / 2.65Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.